Search This Blog

Wednesday, February 25, 2026

Plus Therapeutics wins AMA approval for new Category III CPT code

 

Plus Therapeutics wins AMA approval for new Category III CPT code for REYOBIQ convection-enhanced delivery in brain cancers

  • Code covers convection-enhanced delivery of REYOBIQ for recurrent glioblastoma and pediatric brain cancer indications.
  • New Category III CPT code supports future reimbursement and broader commercialization efforts for Plus Therapeutics' REYOBIQ therapy.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)